1. Sublingual Allergy Treatment

2. Sublingual Immunotherapy Immunotherapy is widely used by allergy specialists because it treats the underlying cause of allergic reactions instead of temporarily alleviating symptoms. Immunotherapy is designed to gradually desensitize the immune system to specific allergens. Patients receive small doses of a specific allergen(s) – not enough to cause a full-blown allergic reaction, but enough to build up a tolerance. Immunotherapy can potentially lead to remission of allergy symptoms, even after discontinuing treatment. seroSLIT® compounding Rx offers an innovative turn-key solution for medical practices interested in offering sublingual immunotherapy to their patients suffering from allergic diseases. Our approach is based on strong science, research, and a commitment to providing unparalleled customer service.

3. Seroslit Advantage seroSLIT has been favorably received by the many medical practitioners who have integrated the service into their practice, and have already started treating patients with sublingual allergy drops. Physicians say they are now able to meet the needs of a greater pool of allergy patients, support staff find that the service easily fits into the practice’s existing infrastructure, and patients enjoy a customized treatment that produces long-lasting results.

4. Sublingual Immunotherapy Dosing Protocols Sublingual immunotherapy (SLIT) treatment regimens typically involve a build-up phase and a maintenance phase. During the build-up phase, gradually increasing doses of allergy drops are administered, until an effective therapeutic dose is reached. The effective therapeutic dose is administered throughout the maintenance phase. Many patients are able to achieve lasting remission of allergy symptoms upon completing a full course of sublingual immunotherapy. A universally accepted dosing schedule for sublingual immunotherapy is not known at this time. There are currently no allergen extracts that have FDA approval for use in sublingual immunotherapy. The use of sublingual immunotherapy in the United States is considered to be an off-label use of an FDA-approved allergen extracts. The optimal dosing ranges for individual antigens have not been determined. The length of the build-up phase, frequency of dosing during build-up and maintenance, and effective maintenance dose is determined by the ordering physician.

5. For more information please visit our website http://www.serologix.com http://www.serologix.com